Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Profiling of the kinome of cytomegalovirus-infected cells reveals the functional importance of host kinases Aurora A, ABL and AMPK.

Hutterer C, Wandinger SK, Wagner S, Müller R, Stamminger T, Zeitträger I, Godl K, Baumgartner R, Strobl S, Marschall M.

Antiviral Res. 2013 Aug;99(2):139-48. doi: 10.1016/j.antiviral.2013.04.017. Epub 2013 May 4.

PMID:
23648710
2.

Human kinome profiling identifies a requirement for AMP-activated protein kinase during human cytomegalovirus infection.

Terry LJ, Vastag L, Rabinowitz JD, Shenk T.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3071-6. doi: 10.1073/pnas.1200494109. Epub 2012 Feb 6.

3.

Digitoxin Suppresses Human Cytomegalovirus Replication via Na+, K+/ATPase α1 Subunit-Dependent AMP-Activated Protein Kinase and Autophagy Activation.

Mukhopadhyay R, Venkatadri R, Katsnelson J, Arav-Boger R.

J Virol. 2018 Feb 26;92(6). pii: e01861-17. doi: 10.1128/JVI.01861-17. Print 2018 Mar 15.

4.

Drug targets in cytomegalovirus infection.

Andrei G, De Clercq E, Snoeck R.

Infect Disord Drug Targets. 2009 Apr;9(2):201-22. Review.

PMID:
19275707
5.

Kinome Profiling Identifies Druggable Targets for Novel Human Cytomegalovirus (HCMV) Antivirals.

Arend KC, Lenarcic EM, Vincent HA, Rashid N, Lazear E, McDonald IM, Gilbert TS, East MP, Herring LE, Johnson GL, Graves LM, Moorman NJ.

Mol Cell Proteomics. 2017 Apr;16(4 suppl 1):S263-S276. doi: 10.1074/mcp.M116.065375. Epub 2017 Feb 25.

6.

Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses.

Efferth T, Marschall M, Wang X, Huong SM, Hauber I, Olbrich A, Kronschnabl M, Stamminger T, Huang ES.

J Mol Med (Berl). 2002 Apr;80(4):233-42. Epub 2001 Dec 8.

PMID:
11976732
7.

Effective inhibition of HCMV UL49 gene expression and viral replication by oligonucleotide external guide sequences and RNase P.

Zhang W, Li H, Li Y, Zeng Z, Li S, Zhang X, Zou Y, Zhou T.

Virol J. 2010 May 18;7:100. doi: 10.1186/1743-422X-7-100.

8.

Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives.

Mercorelli B, Lembo D, Palù G, Loregian A.

Pharmacol Ther. 2011 Sep;131(3):309-29. doi: 10.1016/j.pharmthera.2011.04.007. Epub 2011 Apr 28. Review.

PMID:
21570424
9.

HCMV targets the metabolic stress response through activation of AMPK whose activity is important for viral replication.

McArdle J, Moorman NJ, Munger J.

PLoS Pathog. 2012 Jan;8(1):e1002502. doi: 10.1371/journal.ppat.1002502. Epub 2012 Jan 26.

10.

Inhibition of cytomegalovirus immediate early gene expression: a therapeutic option?

Scholz M, Doerr HW, Cinatl J.

Antiviral Res. 2001 Mar;49(3):129-45. Review.

PMID:
11428240
11.

Inhibition of human cytomegalovirus immediate-early gene expression by cyclin A2-dependent kinase activity.

Oduro JD, Uecker R, Hagemeier C, Wiebusch L.

J Virol. 2012 Sep;86(17):9369-83. doi: 10.1128/JVI.07181-11. Epub 2012 Jun 20.

12.

Regulatory roles of protein kinases in cytomegalovirus replication.

Marschall M, Feichtinger S, Milbradt J.

Adv Virus Res. 2011;80:69-101. doi: 10.1016/B978-0-12-385987-7.00004-X. Review.

PMID:
21762822
14.

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Brümmendorf TH.

Blood. 2008 Apr 15;111(8):4355-64. doi: 10.1182/blood-2007-09-113175. Epub 2008 Feb 11.

15.

Identification of lead anti-human cytomegalovirus compounds targeting MAP4K4 via machine learning analysis of kinase inhibitor screening data.

Strang BL, Asquith CRM, Moshrif HF, Ho CM, Zuercher WJ, Al-Ali H.

PLoS One. 2018 Jul 26;13(7):e0201321. doi: 10.1371/journal.pone.0201321. eCollection 2018.

16.

Structural basis for potent inhibition of the Aurora kinases and a T315I multi-drug resistant mutant form of Abl kinase by VX-680.

Cheetham GM, Charlton PA, Golec JM, Pollard JR.

Cancer Lett. 2007 Jun 28;251(2):323-9. Epub 2007 Jan 19.

PMID:
17240048
17.

PD0084430: a non-nucleoside inhibitor of human cytomegalovirus replication in vitro.

Meyer AL, Bruening EE, Dunkle WE, Booth RJ, Steinbaugh BA, Vara Prasad JV.

Antiviral Res. 2001 Dec;52(3):289-300.

PMID:
11675146
18.

Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo.

Schleiss M, Eickhoff J, Auerochs S, Leis M, Abele S, Rechter S, Choi Y, Anderson J, Scott G, Rawlinson W, Michel D, Ensminger S, Klebl B, Stamminger T, Marschall M.

Antiviral Res. 2008 Jul;79(1):49-61. doi: 10.1016/j.antiviral.2008.01.154. Epub 2008 Feb 22.

PMID:
18329738
19.

Geldanamycin, a potent and specific inhibitor of Hsp90, inhibits gene expression and replication of human cytomegalovirus.

Basha W, Kitagawa R, Uhara M, Imazu H, Uechi K, Tanaka J.

Antivir Chem Chemother. 2005;16(2):135-46.

PMID:
15889536
20.

Human cytomegalovirus-inhibitory flavonoids: studies on antiviral activity and mechanism of action.

Evers DL, Chao CF, Wang X, Zhang Z, Huong SM, Huang ES.

Antiviral Res. 2005 Dec;68(3):124-34. Epub 2005 Sep 15.

PMID:
16188329

Supplemental Content

Support Center